Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: Focus on brentuximab vedotin

OncoTargets and Therapy

Volumn 7, Issue , 2013, Pages 45-56

  Chen, Xueyan ^a   Soma, Lorinda A ^a   Fromm, Jonathan R ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Brentuximab vedotin; CD30; Classical Hodgkin lymphoma; SGN 35; Systemic anaplastic large cell lymphoma

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; GEMCITABINE; IRATUMUMAB; PREDNISONE; SGN 30; VINBLASTINE; VINCRISTINE;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CD30 POSITIVE LYMPHOMA; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG STABILITY; DRUG WITHDRAWAL; FATIGUE; FEVER; HODGKIN DISEASE; HUMAN; IMMUNOGENICITY; LARGE CELL LYMPHOMA; LYMPHOMA; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NK T CELL LYMPHOMA; NONHUMAN; PERIPHERAL NEUROPATHY; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; REVIEW; SALVAGE THERAPY; T CELL LYMPHOMA; THROMBOCYTOPENIA; VOMITING;

EID: 84890948163     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S39107     Document Type: Review

References (101)

1. Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol. 2009;13(3):235-244.
2. Evens AM, Hutchings M, Diehl V. Treatment of Hodgkin lymphoma: the past, present, and future. Nat Clin Pract Oncol. 2008;5(9):543-556.
3. Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124-4130.
4. Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007;25(19): 2764-2769.
5. Forero-Torres A, Leonard JP, Younes A, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146(2):171-179.
6. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-241.
7. Kelly KM, Hodgson D, Appel B, et al. Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer. 2013;60(6):972-978.
8. Kanzler H, Küppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996;184(4):1495-1505.
9. Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer. 2009;9(1):15-27.
10. Eichenauer DA, Engert A, Dreyling M; ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22 Suppl 6: vi55-vi58.
11. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051-1054.
12. Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2006;12(10): 1065-1072.
13. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359(9323):2065-2071.
14. Burroughs LM, O'Donnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14(11):1279-1287.
15. Corradini P, Dodero A, Farina L, et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia. 2007;21(11):2316-2323.
16. Ram R, Gooley TA, Maloney DG, et al. Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17(10):1537-1545.
17. Sarina B, Castagna L, Farina L, et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood. 2010;115(18):3671-3677.
18. Daw S, Wynn R, Wallace H. Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents. Br J Haematol. 2011;152(3):249-260.
19. Friedman DI, Wolden S, Constine DL, et al. AHOD0031: a phase III study of dose-intensive therapy for intermediate risk Hodgkin lymphoma: a report from the children's oncology group. Blood (ASH Annu Meeting Abstr). 2010;116:766.
20. Keller FG, Nachman J, Constine LS, et al. A phase III study for the treatment of children and adolescents with newly diagnosed low risk Hodgkin lymphoma (HL). Blood (ASH Annu Meeting Abstr). 2010;116:767.
21. Kelly KM, Sposto R, Hutchinson R, et al. BEACOPPchemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood. 2011;117(9):2596-2603.
22. Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate-and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009;114(10):2051-2059.
23. Wolden SL, Chen L, Kelly KM, et al. Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma-a report from the Children's Oncology Group. J Clin Oncol. 2012;30(26):3174-3180.
24. Merkel O, Hamacher F, Sifft E, Kenner L, Greil R; European Research Initiative on Anaplastic Large Cell Lymphoma. Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological tools. Mol Cancer Ther. 2011;10(7):1127-1136.
25. Webb TR, Slavish J, George RE, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther. 2009;9(3):331-356.
26. Ferreri AJ, Govi S, Pileri SA, Savage KJ. Anaplastic large cell lymphoma, ALK-negative. Crit Rev Oncol Hematol. 2013;85(2):206-215.
27. Lowe EJ, Gross TG. Anaplastic large cell lymphoma in children and adolescents. Pediatr Hematol Oncol. 2013;30(6):509-519.
28. Lamant L, de Reyniès A, Duplantier MM, et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood. 2007;109(5):2156-2164.
29. Savage KJ, Harris NL, Vose JM, et al; International Peripheral T-Cell Lymphoma Project. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International T-Cell Lymphoma Blood. 2008;111(12):5496-5504.
30. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth Edition. Lyon: IARC Press; 2008.
31. Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood. 2011;117(25):6756-6767.
32. Sibon D, Fournier M, Brière J, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials. J Clin Oncol. 2012;30(32): 3939-3946.
33. Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418-3425.
34. Suzuki R, Kagami Y, Takeuchi K, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood. 2000;96(9):2993-3000.
35. O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182-1189.
36. Mosse YP, Balis FM, Lim MS, et al. Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: a Children's Oncology Group phase I consortium study. J Clin Oncol (ASCO Annu Meeting Abstr). 2012;30:9500.
37. Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med. 2011;364(8):775-776.
38. EM, Dilda I, Villa F, et al. High response rate to crizotinib in advanced, chemoresistant ALK+ lymphoma patients. J Clin Oncol (ASCO Annu Meeting Abstr). 2011;29:e18507.
39. Brugières L, Le Deley MC, Rosolen A, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009;27(6): 897-903.
40. Lamant L, McCarthy K, d'Amore E, et al. Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study. J Clin Oncol. 2011;29(35):4669-4676.
41. Le Deley MC, Reiter A, Williams D, et al; European Intergroup for Childhood Non-Hodgkin Lymphoma. Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood. 2008;111(3):1560-1566.
42. Duckett CS, Gedrich RW, Gilfillan MC, Thompson CB. Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cell Biol. 1997;17(3):1535-1542.
43. Lee SY, Park CG, Choi Y. T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. J Exp Med. 1996;183(2):669-674.
44. Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood. 2000;96(13):4307-4312.
45. Younes A, Aggarwall BB. Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. Cancer. 2003;98(3):458-467.
46. Nadali G, Tavecchia L, Zanolin E, et al. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood. 1998;91(8):3011-3016.
47. Visco C, Nadali G, Vassilakopoulos TP, et al. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. Eur J Haematol. 2006;77(5): 387-394.
48. Zanotti R, Trolese A, Ambrosetti A, et al. Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma. Ann Oncol. 2002;13(12): 1908-1914.
49. Zinzani PL, Pileri S, Bendandi M, et al. Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients. J Clin Oncol. 1998;16(4):1532-1537.
50. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol. 1998;10(6):457-470.
51. Tarkowski M. Expression and a role of CD30 in regulation of T-cell activity. Curr Opin Hematol. 2003;10(4):267-271.
52. Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118(15):4024-4035.
53. Younes A, Carbone A. CD30/CD30 ligand and CD40/CD40 ligand in malignant lymphoid disorders. Int J Biol Markers. 1999;14(3): 135-143.
54. Edinger JT, Clark BZ, Pucevich BE, Geskin LJ, Swerdlow SH. CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol. 2009;33(12):1860-1868.
55. Gerber HP. Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma. Biochem Pharmacol. 2010;79(11):1544-1552.
56. Borchmann P, Treml JF, Hansen H, et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood. 2003;102(10):3737-3742.
57. Heuck F, Ellermann J, Borchmann et al. Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines. J Immunother. 2004;27(5):347-353.
58. Wahl AF, Klussman K, Thompson JD, et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 2002;62(13):3736-3742.
59. Cardarelli PM, Moldovan-Loomis MC, Preston B, et al. In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma. Clin Cancer Res. 2009;15(10):3376-3383.
60. Hammond PW, Vafa O, Jacinto J, et al. A humanized anti-CD30 monoclonal antibody, XmAbTM2513, with enhanced in vitro potency against CD30-positive lymphomas mediated by high affinity Fc-receptor binding. Blood (ASH Annu Meeting Abstr). 2005;106:1470.
61. Lawrence CE, Hammond PW, Zalevsky J, et al. XMAbTM2513, an Fc engineering humanized anti-CD30 monoclonal antibody, has potent in vitro and in vivo activities, and has the potential for treating hematologic malignancies. Blood (ASH Annu Meeting Abstr). 2007;110:2340.
62. Thertulien R, Frankel A, Evens AM, et al. A phase I, open-label, dose-escalation, multidose study of MDX-1401 (defucosylated human anti-CD30 monoclonal antibody) in patients with CD30-positive refractory/relapsed Hodgkin's lymphoma. AACR Meeting Abstr. 2009;1227.
63. Blum KA, Smith M, Fung H, et al. Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: safety, pharmacokinetics (PK), immunogeninicty, and efficacy. J Clin Oncol (ASCO Annu Meeting Abstr). 2009;27(15S):8531.
64. Younes A, Zalevsky J, Blum KA, et al. Evaluation of the pharmacokinetics, immunogenicity, and safety of XmAb(R)2513 in the ongoing study XmAb2513-2501: a phase 1 study of every other week XmAb2513 to evaluate the safety, tolerability, and pharmacokinetics in patients with Hodgkin lymphoma or anaplastic large cell lymphoma. Blood (ASH Annu Meeting Abstr). 2008;112: 5012.
65. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458-1465.
66. Dubowchik GM, Mosure K, Knipe JO, Firestone RA. Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg Med Chem Lett. 1998;8(23):3347-3352.
67. Sanderson RJ, Hering MA, James SF, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res. 2005;11(2 Pt 1):843-852.
68. Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010;16(3):888-897.
69. Gruss HJ, Pinto A, Gloghini A, et al. CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues. Am J Pathol. 1996;149(2):469-481.
70. A, Aldinucci D, Gloghini A, et al. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood. 1996;88(9):3299-3305.
71. Theurich S, Malcher J, Wennhold K, et al. Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission. J Clin Oncol. 2013;31(5):e59-e63.
72. Hamblett KJ, Senter PD, Chace DF, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(20):7063-7070.
73. McDonagh CF, Turcott E, Westendorf L, et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel. 2006;19(7):299-307.
74. Oflazoglu E, Kissler KM, Sievers EL, Grewal IS, Gerber HP. Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol. 2008;142(1):69-73.
75. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812-1821.
76. Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res. 2012;18(1): 248-255.
77. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190-2196.
78. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-2189.
79. Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.
80. de Claro RA, McGinn K, Kwitkowski V, et al. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res. 2012;18(21):5845-5849.
81. Rothe A, Sasse S, Goergen H, et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood. 2012;120(7):1470-1472.
82. Gibb A, Jones C, Bloor A, et al. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica. 2013;98(4):611-614.
83. Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012;119(26):6379-6381.
84. Gopal AK, Ramchandren R, O'Connor OA, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012;120(3):560-568.
85. Sasse S, Rothe A, Goergen H, et al. Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma. 2013;54(10):2144-2148.
86. Seattle Genetics, Inc. Brentuximab Vedotin in With CD30-positive Nonlymphomatous Malignancies. Available from: http://clinicaltrials.gov/show/NCT01461538. NLM identifier: NCT01461538. Accessed November 20, 2013.
87. Albany C, Feldman DR, Garbo LE, Einhorn LH. Antitumor activity of brentuximab vedotin in CD30 positive refractory germ cell tumors. J Clin Oncol. 2013;31 Suppl 6:abstr 327.
88. Seattle Genetics, Inc. A Phase 3 Study of Brentuximab Vedotin (SGN-35) in at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial). Available from: http://clinicaltrials.gov/show/NCT01100502. NLM identifier: NCT01100502. Accessed November 20, 2013.
89. Millennium Pharmaceuticals, Inc. 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma. Available from: http://clinicaltrials.gov/show/NCT01712490. NLM identifier: NCT01712490. Accessed November 20, 2013.
90. Seattle Genetics, Inc. ECHELON-2: A Comparison of Brentuximab Vedotin and CHPWith Standard-of-care CHOPin the Treatment of Patients With CD30-positive Mature T-cell Lymphomas. Available from: http://clinicaltrials.gov/show/NCT01777152. NLM identifier: NCT01777152. Accessed November 20, 2013.
91. National Cancer Institute (NCI). Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger With Relapsed or Refractory Hodgkin Lymphoma. Available from: http://clinicaltrials.gov/show/NCT01780662. NLM identifier: NCT01780662. Accessed November 20, 2013.
92. St. Jude Children's Research Hospital. Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma. Available from: http://clinicaltrials.gov/show/NCT01920932. NLM identifier: NCT01920932. Accessed November 20, 2013.
93. Millennium Pharmaceuticals, Inc. Study of Brentuximab Vedotin (SGN-35) in Pediatric With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma. Available from: http://clinicaltrials.gov/show/NCT01492088. NLM identifier: NCT01492088. Accessed November 20, 2013.
94. Seattle Genetics, Inc. A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma. Available from: http://clinicaltrials.gov/show/NCT01421667. NLM identifier: NCT01421667. Accessed November 20, 2013.
95. M.D. Anderson Cancer Center. SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP). Available from: http://clinicaltrials.gov/show/NCT01352520. NLM identifier: NCT01352520. Accessed November 20, 2013.
96. Seattle Genetics, Inc. Study of Brentuximab Vedotin Combined With RCHOPin Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL). Available from: http://clinicaltrials.gov/show/NCT01925612. NLM identifier: NCT01925612. Accessed November 20, 2013.
97. Fondazione Michelangelo. Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors. Available from: http://clinicaltrials.gov/show/NCT01851200. NLM identifier: NCT01851200. Accessed November 20, 2013.
98. Youn Kim. Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level. Available from: http://clinicaltrials.gov/show/NCT01396070. NLM identifier: NCT01396070. Accessed November 20, 2013.
99. Stanford University. Brentuximab Vedotin in Treating With Advanced Systemic Mastocytosis or Mast Cell Leukemia. Available from: http://clinicaltrials.gov/show/NCT01807598. NLM identifier: NCT01807598. Accessed November 20, 2013.
100. Washington University School of Medicine. Brentuximab Vedotin Prevention of (GVHD) After Mismatched Unrelated Allogeneic Stem Cell Transplantation. Available from: http://clinicaltrials.gov/show/NCT01700751. NLM identifier: NCT01700751. Accessed November 20, 2013.
101. Seattle Genetics, Inc. A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms. Available from: http://clinicaltrials.gov/show/NCT01309789. NLM identifier: NCT01309789. Accessed November 20, 2013.